Trial Profile

A Phase 2, Open-Label Study of IMC-1121B in Combination With Paclitaxel and Carboplatin as First-Line Therapy in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Jul 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ramucirumab (Primary) ; Carboplatin; Paclitaxel
Indications Non-small cell lung cancer
Focus Therapeutic Use
Sponsors Eli Lilly and Company (India) Pvt. Ltd; ImClone Systems

Most Recent Events

25 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
29 Sep 2012 Final results were presented at the Annual Congress of the European Society for Medical Oncology).
22 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com